UroGen presses ahead with RTGel after Botox pairing stumbles in overactive bladder trial

With a recent phase 2 flop for UroGen's hydrogel version of AbbVie's Botox, the biotech may have hit a wall with that particular pairing. But that doesn't mean UroGen has given up on its gel technology's promise for delivering drugs to the bladder.

After making waves earlier this year with the launch of its first drug, Jelmyto—the only approved non-surgical treatment option for a rare form of cancer—UroGen said last week that its reverse thermal hydrogel (RTGel) in combination with Botox failed to curb urinary incontinence episodes in overactive bladder patients.